The association between diabetes and cancer risk remains controversial. Hence, we examined whether midlife diabetes is related to the risk of cancer in late-life, and whether genetic and early-life environmental factors play a role in this association. This study included 25,154 twin individuals born in 1958 or earlier from the Swedish Twin Registry. Information on cancer diagnosis in late life (aged 65) during 1998-2014, was derived from the National Patient and Cancer Registries. Diabetes was ascertained based on self-or informant-reported history, patient registry and antidiabetic medication use. Midlife diabetes was defined when diabetes was diagnosed before 65 years. Data were analyzed following two strategies: (i) unmatched case-control analysis for all participants using generalized estimating equation (GEE) models, and (ii) co-twin control analysis for cancer-discordant twin pairs using conditional logistic regression. Overall, 1,766 (7.0%) had midlife diabetes and 5,293 (21.0%) had cancer in late-life. In multiadjusted GEE models, the odds ratios (95% CIs) of diabetes were 10.55 (2.95-37.67) for pharynx cancer, 5.78 (1.72-19.40) for small intestine cancer, 2.37 (1.14-4.91) for liver cancer and 0.48 (0.35-0.67) for prostate cancer. In people with diabetes, diabetes duration was dose-dependently associated with cancer risk. In conditional logistic regression analysis of 176 prostate cancer-discordant twin pairs, the association between midlife diabetes and prostate cancer in later life became stronger. Midlife diabetes increases the risk of pharynx, small intestine and liver cancers, but reduces prostate cancer risk in late life. Genetic and early-life environmental factors may partially contribute to the diabetes-prostate cancer association.
Thus far, accumulating evidence indicates type 2 diabetes (hereafter diabetes) is a risk factor for developing cancer, 6, 7 which might be linked to metabolic dysfunction characteristic of diabetes such as hyperglycemia or hyperinsulinemia. 8, 9 However, results have been inconsistent regarding the forms of cancer for which diabetes may be a risk factor. 10, 11 In some studies, diabetes has been associated with increased risk of liver, 12 breast, 13 oropharyngeal, 14 endometrial, 15 bladder 16 and kidney 17, 18 cancers and a decreased risk of prostate cancer. [19] [20] [21] However, other studies did not find such associations. [22] [23] [24] Discrepancies in previous findings can be attributed to the different characteristics of study populations, sample size, time window between diabetes and cancer diagnosis and lack of consideration of possible confounders. 8, 25 Genetic and epidemiological studies have suggested that genetic and early-life environmental factors may have longterm effects on the subsequent risk of diabetes and cancer. 26, 27 Twins generally share their early-life environment and are naturally matched pairs, therefore providing a model to measure whether genetic background and early-life environment are important to the association between diabetes and cancer.
In this study, we aimed to verify the hypothesis that midlife diabetes is associated with the development of cancer in late-life, and the role of genetic and early-life environmental factors in this association. Specifically, we seek to (i) assess the association between midlife diabetes and risk of different forms of cancer in late-life and (ii) explore whether genetic background and early-life environment can explain the diabetes-cancer association using a large nationwide cohort.
Research Design and Methods

Study population
Participants were members of the nationwide Swedish Twin Registry (STR), which was started in the 1960s. 28 Between 1998 and 2002, all living twins in the registry who were born in 1958 or earlier were invited to participate in the Screening across the Lifespan Twin Study (SALT) for a full scale screening through a computer-assisted telephone interview. (Fig. 1 ).
Data collection
Information on demographics (age, sex and educational attainment), lifestyle and anthropometric factors (smoking, binge drinking, weight and height), zygotic status and medication use were based on self-reported data from the STR and SALT survey. 28 Zygosity was dichotomized as monozygotic and dizygotic. Education, defined as the maximum years of formal schooling attained, was dichotomized into <8 versus 8 years. Body mass index (BMI), calculated as weight (kg) divided by squared height (m 2 ), was categorized as <20.0 (underweight), 20-24.9 (normal weight), 25-29.9 (overweight), and 30 (obese). Smoking status was dichotomized as never smoking versus former/current smoker. Binge drinking was categorized as never binge drinking versus past/ current binge drinking. Marital status was grouped into married/cohabited versus single (including divorced). Diabetes and cancer conditions were derived through the National Patient Registry (NPR), which covers all inpatient care in Sweden since the 1960s. Each medical record in the NPR included up to eight discharge diagnoses according to the International Classification of Disease (ICD). The 7th revision (ICD-7)'s codes were used until 1968. Afterward, the 8th revision (ICD-8)'s codes were used until 1986, the 9th revision (ICD-9)'s codes were used till 1996 and since 1997, the 10th revision (ICD-10)'s codes have been employed in the register.
Informed consents were required from all participants. Data collection procedures were approved by the Swedish Data Inspection Board, Stockholm; the Regional Ethics Committee at Karolinska Institutet, Stockholm, Sweden; and, the Institutional Review Board of the University of Southern California, USA.
Assessment of diabetes
Diabetes was ascertained based on self-and informantreported history of diabetes, antidiabetic medication use, and NPR (ICD-7 code 260, ICD-8 and -9 code 250 and ICD-10 codes E10-E14). above, all participants with late-life diabetes (n 5 2,318) were excluded from this study. Duration of diabetes was calculated based on the age of diabetes onset and grouped into 0-9, 10-19 and 20 years. Treatment of diabetes was categorized as diet, oral hypoglycemic drugs, insulin and combined oral hypoglycemic drugs and insulin.
Assessment of cancer
Cancer diagnoses were derived from the NPR and the Swedish Cancer Registry (SCR) between 1998 and 2014. The sitespecific cancer forms, based on ICD codes, included oral, pharynx, esophagus, larynx, bronchus and lung, stomach, small intestine, colon, large intestine, rectum, liver, gallbladder, pancreas, breast, cervix uteri, corpus uteri, ovary, other female genital, prostate, kidney, bladder, melanoma, nonmelanoma, brain/nervous system, endocrine, lymphoma and leukemia. The age of cancer onset was estimated according to the earliest recorded date of cancer in NPR or in the SCR. As mentioned above, all participants with any cancer diagnosed before screening or 65 years of age were excluded from this study (n 5 7,183).
Statistical analyses v
2 test was used to compare proportions and t test to compare means of continuous variables with normal distribution (Mann-Whitney was used when variables were non-normally distributed). Generalized estimating equation (GEE) models were used to analyze the unmatched case-control data with control for the clustering of twins within a pair. Data for the co-twin control design were analyzed by using conditional logistic regression models. In the present analysis, twins are matched and compared within pairs, thus cases and controls are comparable regarding genetic and early-life environmental factors (such as childhood socioeconomic status). 29 Co-twin control analysis has been found to be more informative than unrelated case-control analysis, and it allows matching for unmeasured familial factors related to genetic background and shared early-life environment. 2 If significant differences are only found in GEE analyses and disappear in co-twin control analyses, then genetic and/or shared environmental factors are likely to play a role in the observed associations. In contrast, if significant differences remain similar to those from the GEE when using co-twin control analyses, then the influences of genetic background or early-life shared environment on the observed association are small or null. 2, 28 Logistic regression was used to test the difference in ORs from GEE model and conditional logistic regression by examining the difference of midlife diabetes among unmatched versus co-twin controls. Age, sex, education, BMI, smoking, binge drinking and marital status were considered as potential confounders. In sensitivity analysis with multiple imputation by chained equations, missing information on education (n 5 414 participants, 1.6%), smoking (n 5 375 participants, 1.5%), binge drinking (n 5 437 participants, 1.7%), BMI (n 5 927 participants, 3.7%) and marital status (n 5 3 participants, 0.01%) were imputed using Rubin's rule for pooling estimates to obtain valid statistical inferences. 30 The statistical analyses were performed using Stata SE 14.0 (Stata Corp LP, College Station, TX) and IBM SPSS Statistics 20.0ws (IBM Corp, New York, NY).
Results
The 25,154 twin individuals included 11,900 (47.3%) men and 13,254 (52.7%) women. Of the participants, 1,766 (7.0%) had midlife diabetes and 5,293 (21.0%) had cancer in latelife. Compared to diabetes-free participants, those with midlife diabetes were younger, more likely to be male, smokers, single, binge drinking, and had higher BMI (Table 1 ). In patients with diabetes, participants with cancer were older, and had longer diabetes duration compared to participants without cancer (Table 2) . In multi-adjusted GEE models, compared to diabetes-free participants, those with midlife diabetes had significantly higher risk of cancer in pharynx (OR 10.55, 95% CI: 2.95-37.67), small intestine (OR 5.78, 95% CI: 1.72-19.40) and liver (OR 2.37, 95% CI: 1.14-4.91). In multi-adjusted stratified analyses by sex, compared to men without midlife diabetes, men with midlife diabetes had a 52% (OR 0.48, 95% CI: 0.35-0.67) reduced risk of late-life prostate cancer. No significant association between midlife diabetes and later life breast cancer in women was shown (Table 3 ). Cancer Epidemiology Abbreviations: NA, not available due to too few cases; (2), no case due to gender related cancer.
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Model 1 was unadjusted and Model 2 was adjusted for age, education, body mass index, smoking, binge drinking and marital status.
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Bao et al. Table 4 shows the risk of late-life cancer in relation to diabetes duration and treatment. Within diabetes participants, those with longer diabetes duration had a higher cancer risk than those with shorter duration. Additionally, duration of diabetes was dose-dependently associated with cancer risk. After multi-adjustment, the magnitude of the effect decreased but remained statistically significant. Considering that people with longer duration of diabetes might be older and cancer risk increases in older population, we performed stratified analysis by age (<55 vs 55 years) to rule out the influence of age on this association. We found that the association became nonsignificant in the younger group due to small sample, but it still remained significant in the 55 year old group after multiadjustment suggesting that the dose-dependent association might be independent of age. No significant associations were found between diabetes treatment and late-life cancer risk.
Co-twin control analyses were not performed for the associations of midlife diabetes and pharynx, small intestine and liver cancers due to limited number of cases. In the co-twin control analysis, the associations between midlife diabetes and late-life prostate cancer still remained significant and became stronger (OR 0.11, 95% CI: 0.03-0.52), after multi-adjustment for family environmental and genetic factors ( Table 5) .
The difference between the ORs of prostate cancer related to midlife diabetes from GEE model based on entire male participants (multi-adjusted OR 0.48, 95% CI: 0.35-0.67) and from conditional logistic model based on prostate cancerdiscordant pairs (multi-adjusted OR 0.11, 95% CI: 0.03-0.52) was tested by comparing midlife diabetes among the unmatched and matched controls. The difference of midlife diabetes among unmatched versus co-twin controls was statistically significant (OR 1.71, 95% CI: 1.08-2.71) suggesting that some familial factors or genes may partially contribute to the diabetes-prostate cancer association, but cannot fully account for it.
Discussion
In this large-scale, nationwide, population-based Swedish twins study, we found that (i) midlife diabetes was significantly associated with increased risk of pharynx, small intestine, and liver cancers, (ii) in people with diabetes, diabetes duration was dose-dependently associated with the increased cancer risk, (iii) midlife diabetes was related to a decreased risk of prostate cancer, and in the co-twin control analysis controlling for familial and genetic factors, this association became stronger suggesting genetic and shared early-life environmental factors might partially contribute to the diabetesprostate cancer association.
We found that midlife diabetes was associated with an increased risk of pharynx cancer. The few previous studies on the association between diabetes and pharynx cancer showed inconsistent results. A prevalence study among U.S. adults indicated that diabetes is not a risk factor for pharynx cancer after adjusting for multiple variables. 31 On the other hand, two studies reported diabetes had higher risk of pharynx cancer, 14,32 whereas a case-control study reported a positive association between diabetes and pharynx cancer in men, but not in women. 33 Regarding small intestine cancer, we found that adults with midlife diabetes had higher risk of small intestine cancer. Our results are in line with those reported by some studies showing that people with diabetes have 1.5-to 2.2-fold Cancer Epidemiology higher risk of small intestine cancer. 3, 12 However, another study showed no association between diabetes and small intestine cancer in women. 34 These discrepant findings might reflect methodological differences in study designs, study populations, and not taking into account the time window between the occurrence of diabetes and cancer.
The association between diabetes and liver cancer has been reported in a number of studies. In line with previous studies, we found that midlife diabetes confers about 2.4-fold risk of liver cancer, especially in men. A cohort study indicated that patients with diabetes had more than twofold greater risk of liver cancer after 2 to 11 years follow-up. 35 Patients diagnosed with diabetes before 50 years had about threefold higher risk of liver cancer. 36 Results from meta-analysis also showed an increased risk of liver cancer in diabetic patients. 37, 38 However, other cohort studies showed no evidence for the liver cancer-diabetes link. 23, 39, 40 Different follow-up times and diabetes duration might explain these inconsistent results. Hepatocellular carcinoma risk has been correlated with long duration of diabetes. 41 In this study, we observed about 50% lower risk of prostate cancer in men with midlife diabetes, consistent with previous studies. 19, 22, 34 A meta-analysis of 45 studies reported 14% risk reduction of prostate cancer in diabetic patients. 42 Furthermore, two other studies provided evidence for an inverse association between diabetes and prostate cancer. 20, 43 A few previous studies have reported positive or no associations, likely due to small sample size or short follow-up time. 24, 44 Men with diabetes have lower circulating testosterone concentrations, 45 and decreased testosterone may reduce the risk of prostate cancer. 46, 47 Additionally, antidiabetic drugs, such as metformin, can directly influence the prostate cancer growth by inhibiting the proliferation, migration and invasion of the cancer cells. 48 In co-twin control analyses, the association of diabetes with prostate cancer became stronger suggesting that some familial factors or genes may partially contribute to the diabetes-cancer association, but cannot fully account for it. Further studies are needed to identify which are the familial factors or genes that play a role in such an association.
The mechanisms underlying the association between diabetes and cancer remain unclear, but a possible role of long-term hyperinsulinemia, hyperglycemia and inflammation has been hypothesized. 8 Cancer cells express insulin and insulin-like growth factor (IGF) receptors. The general metabolic function of the insulin receptor is to mediate the cellular mitogenesis; however, it can also directly stimulate cancer cell proliferation and metastasis. 8 Additionally, after IGF-I receptors are activated, the subsequent signaling pathways can stimulate cell proliferation, also for cancer cells, and inhibit cell apoptosis, thus, promoting the migration of cancerogenic cells in different body organs. 8 Hyperglycemia may directly provide glucose to cancer cells promoting their proliferation by enhancing oxidative stress. 49, 50 Our finding on a dose-dependent association for which a higher risk of cancer in late-life is associated with a longer duration of diabetes supports the proposed mechanism. Future experimental studies exploring to what extent hyperinsulinemia, hyperglycemia and inflammation interact to promote late-life-specific forms of cancer are needed.
This study has several strengths. First, the large nationwide population-based twin sample allowed us to examine the effect of midlife diabetes on late-life cancer risk, and the simultaneous potential influence of genetic and early-life familial factors with sufficient power. Second, previous studies suggested that new-onset diabetes might be the first symptom of an otherwise asymptomatic cancer. 51 By including only midlife diabetes and late-life cancer in our study, we could minimize the possibility of reverse causation. Third, we use GEE modeling, which is more appropriate than logistic regression models in matched case-control design, as it accounts for the clustering of twins within a pair. However, some limitations need to be pointed out. First, blood glucose was not available in the STR or SALT. Therefore, given the higher prevalence of undiagnosed diabetes in elderly people, 52 a small number of subjects with diabetes might have been misclassified as diabetes-free. However, this would have led to an underestimation of the observed main associations. Second, despite a large sample size, the number of cases was small for some of the sitespecific cancer forms, thus limiting the power and possibility to perform the co-twin control analyses for these cancers. Third, as both monozygotic and dizygotic (sharing only the 50% of genetic background) twins were included in co-twin matched case control analyses, we could not completely control for the genetic background. Fourth, both diabetes and cancer are associated with greater mortality, which may lead to an underestimation of the strength of the true associations. Finally, although some lifestyle related factors in midlife such as smoking, binge drinking and BMI were taken into account in the analysis, but diets and physical activity could not be controlled for due to data unavailable for all participants.
In conclusion, our results show that midlife diabetes is associated with an increased risk of site-specific cancers in the pharynx, small intestine and liver. Duration of diabetes is dose-dependently associated with the risk of these cancers. Furthermore, diabetes is associated with a reduced risk of prostate cancer, and genetic and early-life environmental factors may partially contribute to the diabetes-prostate cancer association. Our study highlights the need of early detection of cancers in patients with diabetes. In particular, a high priority should be given to screening program to prevent latelife cancer in individuals with diabetes.
